Abstracts Archive - Page 1750 of 2425 - ACR Meeting Abstracts

Abstract Number: 910 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Rishi J. Desai¹, Daniel H. Solomon², Sebastian Schneeweiss³, Goodarz Danaei⁴, Katherine Liao⁵ and Seoyoung C. Kim⁶, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Harvard School of Public Health, Boston, MA, ⁵Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Results from several small studies support the potential blood pressure lowering effect of tumor necrosis factor (TNF)-a inhibitors in rheumatoid arthritis (RA) patients. Yet,…
Abstract Number: 911 • 2015 ACR/ARHP Annual Meeting
Patients with Rheumatoid Arthritis Are at Increased Risk of Both Ischemic and Non-Ischemic Heart Failure
Ängla Mantel¹, Marie Holmqvist¹, Daniel Andersson^2,3, Lars Lund^2,3 and Johan Askling^4,5, ¹Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Cardiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Karolinska university hospital, Cardiology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁴Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Studies among unselected patients with rheumatoid arthritis (RA) suggest increased risks of both ischemic and non-ischemic heart failure (HF). Since the risk of these…
Abstract Number: 912 • 2015 ACR/ARHP Annual Meeting
Secondary Preventive Pharmacotherapy and Longterm Outcomes Following Acute Coronary Events in Patients with Prevalent Rheumatoid Arthritis
Ängla Mantel¹, Marie Holmqvist¹, Tomas Jernberg², Solveig Wållberg-Jonsson³ and Johan Askling^4,5, ¹Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Section of Cardiology, Department of medicine, Karolinska University Hospital, Stockholm, Sweden, ³Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁴Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Suboptimal use of secondary preventive pharmacotherapies after acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) has been suggested to contribute to an…
Abstract Number: 913 • 2015 ACR/ARHP Annual Meeting
A Comparison of Physician Based and Patient Based Criteria for the Diagnosis of Fibromyalgia
Frederick Wolfe¹, Mary-Ann Fitzcharles², Don Goldenberg³, Winfried Häuser⁴, Robert S. Katz⁵, Philip J. Mease⁶, Anthony Russell⁷, Jon Russell⁸ and Brian Walitt⁹, ¹National Data Bank, Wichita, KS, ²MGH, Montreal, QC, Canada, ³Newton-Wellesley Hospital, Newton, MA, ⁴Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany, ⁵Rush University Medical Center, Chicago, IL, ⁶Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ⁷Medicine, University of Alberta, Edmonton, AB, Canada, ⁸Fibromyalgia Research and Consulting, San Antonio, TX, ⁹National Institutes of Health, National Institute of Nursing Research, Bethesda, DC
Background/Purpose: The American College of Rheumatology (ACR) 2010 preliminary criteria for the diagnosis of fibromyalgia requires ascertainment of pain extent and symptoms by physicians. The…
Abstract Number: 914 • 2015 ACR/ARHP Annual Meeting
When Fibromyalgia Criteria Misclassify
Frederick Wolfe¹ and Winfried Häuser², ¹National Data Bank, Wichita, KS, ²Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany
Background/Purpose : The 2010 American College of Rheumatology (ACR) preliminary criteria for the diagnosis of fibromyalgia (FM2010) and its extension for clinical research by patient self-report…
Abstract Number: 915 • 2015 ACR/ARHP Annual Meeting
Defining Pain for Fibromyalgia Criteria: Multi-Site or Widespread? an Analysis of Data from Four UK Population-Based Studies
Gary J. Macfarlane¹, Linda E. Dean¹, Robert Bennett², Leslie J. Crofford³, Abimbola Ayorinde¹, Elisa Fluess¹, Daniel J. Clauw⁴, Mary-Ann Fitzcharles⁵, Don Goldenberg⁶, Eduardo Paiva⁷, Roland Staud⁸ and Lesley Arnold⁹, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²SN-Office of Research & Development, Oregon Health & Science Univ, Portland, OR, ³Medicine, Vanderbilt University, Nashville, TN, ⁴Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵MGH, Montreal, QC, Canada, ⁶Newton-Wellesley Hospital, Newton, MA, ⁷Sociedade Brasileira de Reumatologia, São Paulo, Brazil, ⁸University of Florida, Gainesville, FL, ⁹University of Cincinnati, Cincinnati, OH
Background/Purpose: The 1990 criteria for fibromyalgia (FM) remain the only set approved by the American College of Rheumatology (ACR). They require that pain be both…
Abstract Number: 916 • 2015 ACR/ARHP Annual Meeting
Assessing Alternative Selection Criteria for Fibromyalgia Patients within a Multicenter Chronic Pain Claims Database
Mark Gostine¹, Fred Davis¹, Bradley Roberts², Rebecca Risko², Joseph Cappelleri³, Michael Asmus⁴, Andrew Clair⁵ and Alesia Sadosky⁶, ¹Michigan Pain Consultants, PC, Grand Rapids, MI, ²ProCare Systems, Inc., Grand Rapids, MI, ³Biostatistics, Pfizer, Inc., Groton, CT, ⁴North American Medical Affairs, Pfizer, Inc., Middleton, WI, ⁵Pfizer Inc., New York, NY, ⁶Pfizer Inc,, New York, NY
Background/Purpose: Diagnosing FM is difficult because there is no specific laboratory test to confirm the disorder. Billing practices dictate that physicians assign ICD-9-CM (Corresponding International…
Abstract Number: 917 • 2015 ACR/ARHP Annual Meeting
Chronic Widespread Pain in Adolescents Is Highly Associated to Stress and Anxiety
Stefan Bergman^1,2,3, Ann Bremander^1,3,4, Anna-Carin Bergman⁵ and Sofia Brorsson⁶, ¹FoU Spenshult, Halmstad, Sweden, ²Primary Health Care Unit, Department of Public Health and Community Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴School of Business, Engineering and Science, Halmstad University, Halmstad, Sweden, ⁵Sannarpsgymnasiet, Halmstad, Sweden, ⁶Health and Welfare, Dalarna University, Falun, Sweden
Background/Purpose: Chronic widespread pain (CWP), one of the hallmarks of fibromyalgia, is not uncommon in adolescents and it has previously been shown that adolescents with…
Abstract Number: 918 • 2015 ACR/ARHP Annual Meeting
Assessment of the Temporal Variation of the Fibromyalgia Patient Profile Between 2005 and 2013: Do Guidelines Inform Clinical Care?
Angeliki Karellis^1,2, Emmanouil Rampakakis¹, Peter A. Ste-Marie³, Yoram Shir³, John S. Sampalis^1,4 and Mary-Ann Fitzcharles^3,5, ¹JSS Medical Research, St-Laurent, QC, Canada, ²Department of Surgery, McGill University, Montreal, QC, Canada, ³Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In the last decade, interest in fibromyalgia (FM) has increased with the publication of revised diagnostic criteria and clinical guidelines. The 2010 and revised…
Abstract Number: 919 • 2015 ACR/ARHP Annual Meeting
Automated Case Identification of Lupus from an Electronic Health Record Using Novel Informatics Approaches
Sara G. Murray¹, Chris Tonner², Ben J. Marafino³, Sarah Haserodt⁴, Gabriela Schmajuk⁵ and Jinoos Yazdany³, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, University of California, San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Internal Medicine, California Pacific Medical Center, San Francisco, CA, ⁵San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) can be difficult to study given the relatively low prevalence of the disease. While we are now collecting a…
Abstract Number: 920 • 2015 ACR/ARHP Annual Meeting
Patient Preferences for the Development of a Mobile Health (mHealth) Application (App) for Systemic Lupus Erythematosus (SLE) Patients: A Qualitative Study
Alana B. Levine¹, Adena Batterman², VP Bykerk¹, Aislinn Crank³, Su Jin Kim⁴, Juliette Kleinman⁵, Laura Leuenberger¹, Laura Robbins⁶, Jillian A. Rose³, Jane E. Salmon^1,3, Nadine Spring¹, My-Lan Tran⁷ and Roberta Horton², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Social Work Programs, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴School of Social Work, Columbia University, New York, NY, ⁵Patient Care & Quality, Hospital for Special Surgery, New York, NY, ⁶Education & Academic Affairs, Hospital for Special Surgery, New York, NY, ⁷Department of Social Work Programs, Hospital for Special Surgery, New York City, NY
Background/Purpose: SLE patients face many challenges due to lupus, including pain, fatigue, managing medications and appointments, and emotional impact. Patients employ various strategies to manage…
Abstract Number: 921 • 2015 ACR/ARHP Annual Meeting
Poverty Associated with Increase in Damage in SLE over Two-Year Period
Edward H. Yelin¹, Laura Trupin², Jinoos Yazdany² and Stephanie Rush³, ¹University of California, San Francisco, San Francisco, CA, ²Rheumatology, UCSF, SF, CA, ³UCSF, SF, CA
Background/Purpose: Prior research has shown that persons with SLE in poverty have fewer physician visits for SLE and receive lower technical quality of care.…
Abstract Number: 922 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Performance on Quality Measures Pertaining to Assessment of Disease Activity in Juvenile Idiopathic Arthritis
Lara H. Huber^1,2, Murray H. Passo³, Kristen Morella¹, Natasha M. Ruth⁴ and Pediatric Rheumatology Care and Outcomes Improvement Network, ¹Pediatrics, Medical University of South Carolina, Charleston, SC, ²Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ⁴Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Assessment of disease activity is a critical step in the management of patients with juvenile idiopathic arthritis (JIA). The American College of Rheumatology provisional…
Abstract Number: 923 • 2015 ACR/ARHP Annual Meeting
Perceptions of Infectious Risk of Immunosuppressive Medications Among Treating Physicians
Rebecca Sharim¹, Leny Mathew², Michael George³, Preethi Thomas⁴ and Misha Rosenbach⁵, ¹Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Physicians often encounter patients who are treated with immunosuppressive agents and must consider the risk of infection that the medications may pose. We explored…
Abstract Number: 924 • 2015 ACR/ARHP Annual Meeting
Patient and Provider Factors in Optimal Gout Management
Brian Coburn¹, Kayli Bendlin², Harlan Sayles¹ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE
Background/Purpose: Gout is the most common inflammatory arthritis worldwide. Despite its prevalence and the availability of effective therapies, studies have consistently characterized gout quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].